PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to ...

Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary Matrix-M adjuvant technology for use in up to two disease areas. The ...

Matrix-M is Novavax’s proprietary adjuvant technology used to enhance immune response in vaccines. The company noted that this agreement, along with other recently formed partnerships, demonstrates ...

The phase 1/2b clinical trial on R21/Matrix-M malaria vaccine has recently reported the safety and efficacy of booster vaccination at 12 months. The entire report has been published in The Lancet ...

(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavax's Matrix-M adjuvant. The companies have amended ...

Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments.

Per the terms of the agreement, Novavax will receive an upfront payment of $30 million from Pfizer and is eligible to earn up to $500 million in potential development and commercial milestone payments ...